Patient-Reported Outcomes (PROs) Now and into the Future: Multi-Stakeholder Perspectives on Optimizing PRO Evidence Use in Decision-Making across the US Healthcare Continuum.

IF 6 2区 医学 Q1 ECONOMICS
Sharan Randhawa, Adam Gater, Roy Bentley
{"title":"Patient-Reported Outcomes (PROs) Now and into the Future: Multi-Stakeholder Perspectives on Optimizing PRO Evidence Use in Decision-Making across the US Healthcare Continuum.","authors":"Sharan Randhawa, Adam Gater, Roy Bentley","doi":"10.1016/j.jval.2025.08.008","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>Patient-reported outcome measures (PROMs) are tools intended to capture directly from patients how they feel and/or function. They can provide important evidence to support regulatory approval, product labeling, payer reimbursement, and clinical care decisions. However, patient-reported outcome (PRO) evidence remains underutilized in regulatory, payer, and overall healthcare decision-making. This initiative aimed to understand stakeholder perspectives regarding current use of PRO evidence across the US healthcare continuum and opportunities to further advance its use in healthcare-related decision-making.</p><p><strong>Methods: </strong>Three roundtable meetings were convened with an expert panel representing patients/patient advocacy groups, clinicians, PRO experts, payers/purchasers, and policymakers. Meetings were audio-recorded and transcripts were reviewed to identify key discussion points and themes via thematic analysis methods. Group members reviewed, discussed, and commented on findings as they emerged.</p><p><strong>Results: </strong>The themes that emerged on maximizing use of PRO evidence were: 1. Educating stakeholders on its value; 2. Ensuring standardization of PROM development methods, including maximizing patient engagement; 3. Addressing PROM implementation considerations in clinical trials and practice; 4. Effectively communicating PRO evidence to stakeholders; and 5. Encouraging PRO evidence integration into policy and shared clinical decision-making. A five-component framework resulted.</p><p><strong>Conclusions: </strong>PRO evidence is fundamental to patient-focused drug development and clinical care. Collaboration among all stakeholders making decisions related to treatment approval, access, and use is critical to realizing the value of PRO evidence, alongside greater stakeholder transparency regarding how PRO evidence is used to inform decisions. The five-component framework, co-developed by a multistakeholder expert panel, can help to support and enhance these collaborations.</p>","PeriodicalId":23508,"journal":{"name":"Value in Health","volume":" ","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Value in Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jval.2025.08.008","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ECONOMICS","Score":null,"Total":0}
引用次数: 0

Abstract

Objectives: Patient-reported outcome measures (PROMs) are tools intended to capture directly from patients how they feel and/or function. They can provide important evidence to support regulatory approval, product labeling, payer reimbursement, and clinical care decisions. However, patient-reported outcome (PRO) evidence remains underutilized in regulatory, payer, and overall healthcare decision-making. This initiative aimed to understand stakeholder perspectives regarding current use of PRO evidence across the US healthcare continuum and opportunities to further advance its use in healthcare-related decision-making.

Methods: Three roundtable meetings were convened with an expert panel representing patients/patient advocacy groups, clinicians, PRO experts, payers/purchasers, and policymakers. Meetings were audio-recorded and transcripts were reviewed to identify key discussion points and themes via thematic analysis methods. Group members reviewed, discussed, and commented on findings as they emerged.

Results: The themes that emerged on maximizing use of PRO evidence were: 1. Educating stakeholders on its value; 2. Ensuring standardization of PROM development methods, including maximizing patient engagement; 3. Addressing PROM implementation considerations in clinical trials and practice; 4. Effectively communicating PRO evidence to stakeholders; and 5. Encouraging PRO evidence integration into policy and shared clinical decision-making. A five-component framework resulted.

Conclusions: PRO evidence is fundamental to patient-focused drug development and clinical care. Collaboration among all stakeholders making decisions related to treatment approval, access, and use is critical to realizing the value of PRO evidence, alongside greater stakeholder transparency regarding how PRO evidence is used to inform decisions. The five-component framework, co-developed by a multistakeholder expert panel, can help to support and enhance these collaborations.

患者报告的结果(PROs)现在和未来:优化美国医疗保健连续体决策中PRO证据使用的多方利益相关者观点。
目的:患者报告的结果测量(PROMs)是旨在直接从患者那里获取他们的感觉和/或功能的工具。它们可以为支持监管审批、产品标签、付款人报销和临床护理决策提供重要证据。然而,患者报告的结果(PRO)证据在监管、支付方和整体医疗保健决策中仍未得到充分利用。该倡议旨在了解利益相关者对美国医疗保健连续体中PRO证据当前使用的看法,以及进一步推进其在医疗保健相关决策中的使用的机会。方法:召开了三次圆桌会议,由代表患者/患者倡导团体、临床医生、PRO专家、支付方/采购商和政策制定者的专家小组组成。对会议进行录音,并审查会议记录,以便通过专题分析方法确定关键的讨论点和主题。小组成员回顾、讨论和评论这些发现。结果:在最大限度地利用PRO证据方面出现的主题是:1。教育利益相关者其价值;2. 确保PROM开发方法的标准化,包括最大限度地提高患者参与度;3. 解决临床试验和实践中对PROM实施的考虑;4. 有效地与利益相关者沟通PRO证据;和5。鼓励PRO证据纳入政策和共享临床决策。一个由五部分组成的框架由此产生。结论:PRO证据是以患者为中心的药物开发和临床护理的基础。与治疗批准、获取和使用相关决策的所有利益攸关方之间的合作对于实现PRO证据的价值至关重要,同时也对如何使用PRO证据为决策提供信息的利益攸关方提高透明度至关重要。由多利益攸关方专家小组共同制定的五部分框架有助于支持和加强这些合作。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Value in Health
Value in Health 医学-卫生保健
CiteScore
6.90
自引率
6.70%
发文量
3064
审稿时长
3-8 weeks
期刊介绍: Value in Health contains original research articles for pharmacoeconomics, health economics, and outcomes research (clinical, economic, and patient-reported outcomes/preference-based research), as well as conceptual and health policy articles that provide valuable information for health care decision-makers as well as the research community. As the official journal of ISPOR, Value in Health provides a forum for researchers, as well as health care decision-makers to translate outcomes research into health care decisions.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信